Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review

• Published in: Naunyn-Schmiedeberg's archives of pharmacology Vol. 397; no. 5; pp. 2681 - 2699
• Main Authors: Barbalho, Sandra Maria, de Alvares Goulart, Ricardo, Minniti, Giulia, Bechara, Marcelo Dib, de Castro, Marcela Vialogo Marques, Dias, Jefferson Aparecido, Laurindo, Lucas Fornari
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2024; Springer Nature B.V
• Subjects: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology; Adipocytes - drug effects; Adipocytes - metabolism; Adipogenesis; Adipogenesis - drug effects; Animals; Biomedical and Life Sciences; Biomedicine; CCAAT/enhancer-binding protein; Cell culture; Cell Differentiation - drug effects; Clinical trials; Fatty acid-binding protein; Fibronectin; Heterocyclic Compounds, 4 or More Rings; Humans; Kinases; Mice; Neurosciences; Peroxisome proliferator-activated receptors; Pharmacology/Toxicology; Protein Kinase Inhibitors - pharmacology; Proteins; Review; Reviews; rho-Associated Kinases - antagonists & inhibitors; rho-Associated Kinases - metabolism; Sterol regulatory element-binding protein; Systematic review; Therapeutic applications; Casein kinase; KD025; Adipocyte differentiation; ROCK2; Rho-associated kinase; Belumosudil

Rho-associated kinases (ROCKs) are crucial during the adipocyte differentiation process. KD025 ( Belumosudil ) is a newly developed inhibitor that selectively targets ROCK2. It has exhibited consistent efficacy in impeding adipogenesis across a spectrum of in vitro models of adipogenic differentiati...